Xequecal wrote:
[...]
This is where I don't get where you're coming from on the patent angle. All the drug company's profit is derived from their exclusivity period. As soon as that ends, anyone else can sell the drug basically for cost. If you universally allow cheap generic imports, how do they make money? If importing is not allowed during the period of exclusivity, then it's essentially the same system we have now. If it is allowed, then they have no way of recouping their costs as companies will import copies of the drug and sell them for very low prices almost immediately.
Everything prior to this is correct, so I've removed it.
This paragraph is where the problem arises.
Once the patent exclusivity period ends, other companies can
legally produce "generic"copies of the drug. Doing so beforehand requires violation of US Patent law. So for the rest of this post, assume only everything has to do with the next scenario:
Now, if you want to talk parallel engineering of a drug, you could conceivably do that without running afoul of the patent. This is because, as you said, the patent is usually on the process not the compound (although this is, of course, never universally true).
So in the former case, there is no risk to the pharma company. In the latter case, the risk is that somebody comes along and creates, through some cheaper metholodogy, a drug that does the same thing. This could be a risk to the primary pharma company.
However, since the cheaper methods usually are not done within the United States, the FDA will not approve them for import. Thus, places like India and Germany and so forth have cheap generics available to them and we do not.
If, on the other hand, you were to remove the requirement for FDA screening of these drugs, the primary pharma company could reduce their research time and cost. In so doing, all other factors remaining constant, they could lower the price of their drugs. This would then make knock-off generic development much less enticing, because the price undercuts then become far less significant. This is a basic, fundamental risk-return factor in economics (and thus why I was getting frustrated).
It is important, therefore, to note at this juncture that FDA approval requirements came into place against the wishes of pharmaceutical companies.
None of this addresses the price shifting that results from governmental price controls in other countries, but that's a bigger, harder, and more complicated issue.